Supernus Resubmits NDA To FDA For SPN-830 Apomorphine Infusion Device
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) to the FDA for its apomorphine infusion device (SPN-830), aimed at treating motor fluctuations in Parkinson's disease.
August 01, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Supernus Pharmaceuticals has resubmitted its NDA to the FDA for SPN-830, an apomorphine infusion device for Parkinson's disease. This resubmission could lead to FDA approval, potentially boosting the company's stock price.
The resubmission of the NDA indicates progress in the regulatory process, which could lead to FDA approval. Approval would allow Supernus to commercialize SPN-830, potentially increasing revenues and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100